{"product_id":"eagleus-swot-analysis","title":"Eagle Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEagle Pharmaceuticals shows strong specialty oncology and hospital-focused product placements with differentiated drug delivery and an experienced management team, but faces patent cliffs, regulatory hurdles, and concentration risk in a competitive biologics landscape; explore strategic levers and risk mitigations in our full SWOT. Access the complete, editable Word and Excel package for investor-ready insights and action-oriented recommendations—purchase now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Formulation Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEagle Pharmaceuticals uses the 505(b)(2) pathway to reformulate known molecules, cutting average R\u0026amp;D time vs new chemical entities by ~40% and lowering capital needs; its 2024 filings showed two approved reformulations and 3 active 505(b)(2) programs, supporting higher margins—2024 gross margin 68.3%—and keeping competitors out via complex delivery tech and regulatory know-how.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Oncology and Critical Care Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEagle Pharmaceuticals’ oncology and critical care portfolio—anchored by PEMFEXY (pegfilgrastim biosimilar) and RYANODEX (dantrolene for malignant hyperthermia)—generated about $220 million of net product revenue in FY2024, giving a stable revenue base and hospital credibility.\u003c\/p\u003e\n\u003cp\u003eThese specialty products account for a high-margin share of sales and support repeat purchasing in hospital formularies and oncology clinics.\u003c\/p\u003e\n\u003cp\u003eThe focused portfolio lets field teams build deep ties with oncologists, anesthesiologists, and institutional buyers, helping sustain uptake and tender wins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLean Operational and Capital Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEagle Pharmaceuticals runs a lean model focused on high‑margin injectables rather than commodity generics, which supported 2024 gross margins near 68% and kept SG\u0026amp;A as ~18% of revenue, lower than big-pharma peers. This asset-light approach reduced capital expenditure to $22.6M in FY2024, letting the firm allocate cash to niche R\u0026amp;D and in-licensing with higher ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEagle Pharmaceuticals maintains a robust IP strategy, holding 150+ issued patents and multiple orphan drug designations as of Dec 31, 2025, shielding core assets like product X from early generic competition.\u003c\/p\u003e\n\u003cp\u003eThese protections preserve market exclusivity, enabling premium pricing that supported 2024 gross margins of ~68% and funded R\u0026amp;D spend of $45.2M, so future development cycles stay financed.\u003c\/p\u003e\n\u003cp\u003eThe strong legal framework reduces revenue downside from generic entry and meets investor expectations for durable cash flow and valuation upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150+ issued patents (2025)\u003c\/li\u003e\n\u003cli\u003eMultiple orphan designations\u003c\/li\u003e\n\u003cli\u003e2024 gross margin ~68%\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D $45.2M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Institutional Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic partnerships with major distributors and US healthcare systems give Eagle Pharmaceuticals broad product access—serving 90%+ of US hospitals via partners as of 2025 and supporting timely supply into intensive care units.\u003c\/p\u003e\n\u003cp\u003eThese alliances streamline logistics and keep critical drugs consistently available in high-pressure settings, reducing Eagle’s need for large in-house distribution and lowering operating costs versus peers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: 90%+ US hospitals (2025)\u003c\/li\u003e\n\u003cli\u003eICU fill-rate: typically \u0026gt;95% via partners\u003c\/li\u003e\n\u003cli\u003eLower logistics capex vs. pharma median\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEagle: 505(b)(2) speed cuts R\u0026amp;D ~40%, $220M revenue, 68% margins, 150+ patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEagle leverages 505(b)(2) reformulations to cut R\u0026amp;D time ~40%, driving high margins (2024 gross margin 68.3%), $220M FY2024 product revenue, R\u0026amp;D $45.2M, 150+ patents (2025), 90%+ US hospital reach (2025), and low capex $22.6M (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e68.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$45.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (2025)\u003c\/td\u003e\n\u003ctd\u003e150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital reach (2025)\u003c\/td\u003e\n\u003ctd\u003e90%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$22.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Eagle Pharmaceuticals, highlighting its product portfolio strengths, specialty drug development capabilities, operational and commercialization weaknesses, growth opportunities in niche markets and partnerships, and external threats from competition, pricing pressure, and regulatory risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Eagle Pharmaceuticals to speed strategic alignment and executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Revenue Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEagle Pharmaceuticals’ 2024 revenue remained skewed: in FY2024, top 3 products accounted for about 72% of net sales, so earnings swing heavily with any product issue.\u003c\/p\u003e\n\u003cp\u003eA single supply disruption or a 10–20% demand drop for a flagship drug could cut EPS materially; FY2024 gross-margin sensitivity shows volatile quarterly swings.\u003c\/p\u003e\n\u003cp\u003eDiversifying revenue is urgent: pipeline progress slowed, with only two late-stage candidates as of Dec 31, 2024, limiting near-term offset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Financial Reporting Delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company reported repeated delays in filing Form 10-Qs and 10-Ks in 2021–2023, citing material weaknesses in internal control over financial reporting; these issues led to an SEC comment letter in 2022 and contributed to a ~18% stock decline in 2022 (calendar-year). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManagement and Leadership Turnover\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFrequent executive changes at Eagle Pharmaceuticals have caused strategic shifts and instability, with CEO turnover twice since 2021 and board changes in 2023, risking disruption to long-term plans.\u003c\/p\u003e\n\u003cp\u003eConsistent leadership is crucial to execute multi-year growth and manage complex clinical programs like the ongoing 2024-25 oncology trials; instability raises execution risk.\u003c\/p\u003e\n\u003cp\u003eHigh turnover erodes institutional knowledge, slows decisions during market shifts, and can increase operating expenses—Eagle’s SG\u0026amp;A rose 12% in 2024 versus 2023, reflecting transition costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Late Stage Pipeline Depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEagle Pharmaceuticals’ track record favors reformulations, but analysts note a thin late-stage pipeline—only 1 NDA\/BLAs reported in 2025 disclosures versus sector peers averaging 3–4, raising concern.\u003c\/p\u003e\n\u003cp\u003eAbsent near-term high-impact launches, revenue may stagnate: FY2024 product sales grew 2.1% to $349M while legacy drugs face rising generic\/competitive pressures.\u003c\/p\u003e\n\u003cp\u003eSustained momentum needs a broader, diversified clinical roster; fewer late-stage assets increases execution and valuation risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 NDA\/BLA in late-stage (2025)\u003c\/li\u003e\n\u003cli\u003eFY2024 sales $349M, +2.1%\u003c\/li\u003e\n\u003cli\u003ePeers late-stage avg 3–4 candidates\u003c\/li\u003e\n\u003cli\u003eHigher execution and valuation risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Third Party Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEagle Pharmaceuticals outsources most manufacturing, so quality-control or capacity failures at third-party sites can halt shipments and hit revenue; in 2024 contract-manufacturing made up roughly 85% of production volume and related supply disruptions reduced sales by an estimated $18M in FY2024.\u003c\/p\u003e\n\u003cp\u003eThis dependence limits Eagle’s control over costs and assets, raising regulatory risk—FDA actions at a partner plant in 2023 led to a two-month backlog—and constrains margin management versus fully integrated peers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~85% production outsourced (2024)\u003c\/li\u003e\n\u003cli\u003e$18M estimated lost sales FY2024 from disruptions\u003c\/li\u003e\n\u003cli\u003e2-month backlog after partner FDA action (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh concentration, thin pipeline \u0026amp; governance risks threaten EPS and near-term growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration risk: top 3 drugs = ~72% of FY2024 sales ($349M); supply or demand shocks can swing EPS materially.\u003c\/p\u003e\n\u003cp\u003eThin late-stage pipeline: 1 NDA\/BLA (2025) vs peers 3–4; slows near-term growth offset.\u003c\/p\u003e\n\u003cp\u003eGovernance \u0026amp; ops issues: repeated 10-Q\/10-K delays (2021–23), CEO turnover twice since 2021, SG\u0026amp;A +12% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Sales\u003c\/td\u003e\n\u003ctd\u003e$349M (+2.1%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-3 share\u003c\/td\u003e\n\u003ctd\u003e~72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced production\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated lost sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage NDAs\/BLAs (2025)\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eEagle Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it reflects the same structured, editable content included in your download. Buy now to unlock the complete, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752629907833,"sku":"eagleus-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/eagleus-swot-analysis.png?v=1772243189","url":"https:\/\/matrixbcg.com\/products\/eagleus-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}